Technical Analysis for OLMA - Olema Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Down |
| Historical OLMA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 1.91% | |
| NR7 | Range Contraction | 1.91% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | about 15 hours ago |
| 60 Minute Opening Range Breakdown | about 18 hours ago |
| Rose Above Previous Day's High | about 19 hours ago |
| Up 2% | about 19 hours ago |
| Up 1% | about 19 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Hormones Targeted Therapy Epidermal Growth Factor Receptor Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Breast Cancer Treatment Of Breast Cancer Hormones Targeted Therapy Epidermal Growth Factor Receptor Her2 Her2/Neu Estrogen Antiestrogens Estrogen Receptor Selective Estrogen Receptor Degraders Fulvestrant
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 60.27 |
| 52 Week Low | 19.41 |
| Average Volume | 227,090 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 27.78 |
| 20-Day Moving Average | 27.79 |
| 10-Day Moving Average | 27.85 |
| Average True Range | 2.02 |
| ADX | 17.91 |
| +DI | 21.15 |
| -DI | 20.13 |
| Chandelier Exit (Long, 3 ATRs) | 26.70 |
| Chandelier Exit (Short, 3 ATRs) | 30.25 |
| Upper Bollinger Bands | 30.82 |
| Lower Bollinger Band | 24.76 |
| Percent B (%b) | 0.31 |
| BandWidth | 21.80 |
| MACD Line | -0.23 |
| MACD Signal Line | 0.01 |
| MACD Histogram | -0.2364 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 28.01 | ||||
| Resistance 3 (R3) | 27.94 | 27.42 | 27.78 | ||
| Resistance 2 (R2) | 27.42 | 27.07 | 27.45 | 27.71 | |
| Resistance 1 (R1) | 27.03 | 26.85 | 27.22 | 27.10 | 27.63 |
| Pivot Point | 26.50 | 26.50 | 26.60 | 26.54 | 26.50 |
| Support 1 (S1) | 26.12 | 26.16 | 26.31 | 26.18 | 25.65 |
| Support 2 (S2) | 25.59 | 25.94 | 25.63 | 25.57 | |
| Support 3 (S3) | 25.20 | 25.59 | 25.50 | ||
| Support 4 (S4) | 25.27 |
